Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to the Blueprint Medicines Conference Call. At this time, all participants are in listen-only-mode.
Source: insidermonkey.com
📰 Dane Leone News
Page 4 - Dane Leone News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dane Leone. Real-time updates on events, politics, business and more.
Seagen (SGEN) Q4 2022 Earnings Call Transcript
SGEN earnings call for the period ending December 31, 2022.
Source: fool.com
Positive Report for Seagen (SGEN) from Raymond James
Seagen (SGEN – Research Report) received a Buy rating and a $175.00 price target from Raymond James analyst Dane Leone yesterday. The comp...
Source: businessinsider.com
Simulations Plus, Inc. (NASDAQ:SLP) Q1 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Simulations Plus First Quarter Fiscal 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Source: insidermonkey.com
Cytokinetics, Incorporated (CYTK) Q3 2022 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:NASDAQ:CYTK) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Diane Weiser - Senior Vice President, Corporate...
Source: seekingalpha.com
Simulations Plus, Inc. (SLP) Q4 2022 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:NASDAQ:SLP) Q4 2022 Earnings Conference Call October 26, 2022 5:00 PM ET Company Participants Brian Siegel – Hayden IR Shawn O’Connor – Chief Executive...
Source: seekingalpha.com
Bristol Myers Squibb (BMY) Q3 2022 Earnings Call Transcript
BMY earnings call for the period ending September 30, 2022.
Andrew Baum Chris Boerner Chris Shibutani Terence Flynn Morgan Stanley Terence Flynn Giovanni Caforio
Source: fool.com
Bluebird Bio Shares Up 14%; Raymond James Raises Price Target After FDA Approval of Skysona
By Kathryn Hardison Shares of bluebird bio Inc. increased 14% to $6.74 on Tuesday after a Raymond James analyst raised the stock price target for the company on the heels of another approval...
Source: marketscreener.com